Compass Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $432.2M
- Price
- $2.40
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.69%
- Volume
- 2.0M
About
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Quick stats
Shares outstanding180.1M
Computed float115.1M
Float / shares63.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001738021
AI Summary
AI-generated1/37
majorbullishearnings
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported updated Phase 2/3 data for tovecimig showing an overall response rate of 18.0% versus 5.3% for the control arm, achieving a p-value of 0.0228. The company plans to engage the FDA this quarter regarding a potential BLA filing later this year and will present the full dataset at ESMO in October.
Pipeline progression included the initiation of a Phase 2 study for CTX-471 in Q3 and the dosing of the first patients in the Phase 1 study of CTX-10726, with initial data expected in Q4. Additionally, cohort expansions for CTX-8371 are actively enrolling in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer.
Financially, the company reported a net loss of $25.2 million for the second quarter, with cash and marketable securities totaling $180 million. This cash position is expected to fund operations into 2028.
Red flags
- G&A expenses increased 59% year-over-year, driven by pre-commercialization and stock compensation expenses